결핵 진료지침
## 참고문헌
1.  WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
2.  WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022.
3.  WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents. World Health Organization; 2022.
4.  American Academy of Pediatrics.Tuberculosis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2021:786–813.
5.  Official American Thoracic Society/Centers for DiseaseControl and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug–Susceptible Tuberculosis. Clinical Infect Dis. 2016;63:e147–e195.
6.  Garcia–Prats AJ, Frias M, van der Laan L, et al. Delamanid Added to an Optimized Background Regimen in Children with Multidrug–Resistant Tuberculosis: Results of a Phase I/II Clinical Trial. Antimicrob Agents Chemother. 2022;66:e0214421.
7.  Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug–resistant tuberculosis: practice–based recommendations. Am J Respir Crit Care Med 2012; 186:953.
8.  World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO, Geneva 2008.
9.  World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. WHO, Geneva 2016.
10. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed. WHO, Geneva 2014.

VII. 소아청소년 결핵 253